Kura Oncology is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer treatment. Its core products include investigational drugs aimed at treating various malignancies, with a primary focus on precision medicine. Major business segments involve research and development of novel oncology therapies, with revenue primarily derived from partnerships and potential future product sales.
The investment profile of Kura Oncology is more aligned with growth investors, given its focus on developing innovative cancer therapies and the potential for significant future returns. The company does not currently offer dividends, making it less suitable for income-focused investors. The stock may appeal to those with a medium to long-term investment horizon, reflecting the typical timeline for clinical development and commercialization in the biotech sector.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-09-25 | Hold | Sell | Weak momentum and high risk; cautious approach advised. |
| 2026-09-14 | Buy | Hold | Weak momentum and high risk; uncertain growth outlook. |
| 2026-09-06 | Hold | Buy | Strong momentum and improving fundamentals support growth outlook. |
| 2026-08-26 | — | Hold | Strong momentum, but negative EPS raises concerns. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-08-24 | Morgan Stanley | Update | — → 24 | 11.89 |
| 2026-08-24 | Raymond James | Update | — → 24 | 11.89 |
| 2026-06-15 | Bernstein | Update | — → 24 | 9.05 |
| 2026-06-04 | CLSA | Update | — → 24 | 8.655 |
| 2026-06-04 | Wells Fargo | Update | — → 24 | 8.655 |
| 2026-05-28 | Jefferies | Update | — → 24 | 10.24 |
| 2026-05-28 | Oppenheimer | Update | — → 24 | 10.24 |
| 2026-04-14 | Lake Street | Update | — → 23 | 8.72 |
| 2026-03-13 | UBS | Target Lowered | — → 15 | 8.595 |
| 2026-01-13 | Leerink Partners | Target Lowered | 25 → 20 | 9.025 |
